Mandel-Brehm Josh 4

What Happened

• Josh Mandel-Brehm, CEO of Camp4 Therapeutics (CAMP), received a derivative award on 2026-04-01 covering 580,000 shares. The filing reports an acquisition type "A" (grant/award) with a $0.00 per-share amount (no cash paid at grant). This is an equity compensation grant (option/award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (filed promptly).
• Transaction type/code: A (grant/award) as a derivative security; reported price: $0.00; reported total consideration: $0.
• Vesting: Shares underlying the option vest in equal monthly installments over four years commencing from the grant date (footnote F1).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing timeliness: Report appears timely (filed two days after the transaction); no late filing indicated.

Context

• This was a grant of a derivative equity award (options or similar) rather than an exercise or sale. The award vests over time, so it represents future compensation contingent on continued service rather than an immediate change in market exposure. Equity awards to executives are common as retention and incentive tools and do not by themselves signal buying or selling intent.